The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Homo sapiens
收藏NIAID Data Ecosystem2026-03-10 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJNA386866
下载链接
链接失效反馈官方服务：
资源简介：
Double Hit Lymphoma (DHL) were treated with the BRD4 inhibitor 100 nM CPI203 for 6h We used microarrays to uncover the mechanisms underlying CPI203 activity in Double Hit Lymphoma (DHL) Overall design: Global RNA expression was done in three DHL cell lines and two DHL patients treated in vitro with CPI203 for 6h
创建时间：
2017-05-15
